22 September 2021 ORYZON to present new clinical data and corporate updates at international conferences in September and October
21 September 2021 Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with vafidemstat
13 July 2021 ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia
9 July 2021 ORYZON presents safety and efficacy data of vafidemstat from the Phase II ESCAPE trial in severe CoVID-19 patients at ECCMID-2021